ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Infectious Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,440Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 69

$632K Total Retail Price of All Prescriptions

Rank: 28 out of 69

580 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
14% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 580 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

9% of this provider’s 580 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

1% of this provider’s 9,951 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 44%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $222 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
SIMVASTATIN 681 648 1 1
METOPROLOL TARTRATE 519 494 2 14
WARFARIN SODIUM 395 391 3 20
LISINOPRIL 389 362 4 2
AMLODIPINE BESYLATE 315 313 5 6
ATORVASTATIN CALCIUM 303 281 6 19
FUROSEMIDE 295 290 7 9
ATENOLOL 291 279 8 13
OMEPRAZOLE 289 273 9 3
DONEPEZIL HCL 265 265 10 53
LEVOTHYROXINE SODIUM 213 207 11 7
POTASSIUM CHLORIDE 183 182 12 33
METFORMIN HCL 180 174 13 12
HYDROCODONE-ACETAMINOPHEN 174 166 S3 14 26
CITALOPRAM HBR 159 153 15 23
ALENDRONATE SODIUM 155 152 16 30
ZOLPIDEM TARTRATE 149 140 17 28
TRIAMTERENE-HCTZ 138 137 18 84
HYDROCHLOROTHIAZIDE 129 128 19 10
TAMSULOSIN HCL 128 128 20 41
PRAVASTATIN SODIUM 127 126 21 16
TRAZODONE HCL 122 122 22 27
ALLOPURINOL 116 116 23 35
GLYBURIDE 112 100 R 24 60
PREDNISONE 112 105 24 56
LOSARTAN POTASSIUM 96 93 26 36
OXYCODONE-ACETAMINOPHEN 90 67 S2 27 29
GABAPENTIN 86 83 28 15
SPIRONOLACTONE-HCTZ 82 77 29 98
MIRTAZAPINE 80 80 30 54
CLOPIDOGREL 80 77 30 57
DIGOXIN 78 78 32 51
PROAIR HFA 75 73 33 24
ADVAIR DISKUS 74 68 34 76
NAMENDA 68 68 35 66
METOPROLOL SUCCINATE 68 68 35 21
PANTOPRAZOLE SODIUM 65 65 37 37
CRESTOR 58 58 38 31
DIOVAN 57 57 39 79
SPIRONOLACTONE 57 57 39 48
SERTRALINE HCL 56 56 41 39
CARVEDILOL 55 51 42 38
FLUTICASONE PROPIONATE 54 35 43 55
ZETIA 54 54 43 129
TRAMADOL HCL 54 43 43 22
SYNTHROID 52 52 46 137
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.